Ruxolitinib Versus Best Available Therapy for PV Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial

被引：4

作者：

Harrison, Claire ^{[1
]}

Nangalia, Jyoti ^{[2
,3
,4
]}

Boucher, Rebecca H. ^{[5
]}

Jackson, Aimee ^{[5
]}

Yap, Christina ^{[5
,6
]}

O'Sullivan, Jennifer ^{[7
,8
,9
]}

Fox, Sonia ^{[10
]}

Ailts, Isaak ^{[11
]}

Dueck, Amylou C. ^{[12
]}

Geyer, Holly L. ^{[11
]}

Mesa, Ruben ^{[13
]}

Dunn, William ^{[4
]}

Nadezhdin, Eugene ^{[3
]}

Curto-Garcia, Natalia ^{[7
]}

Green, Anna ^{[14
]}

Wilkins, Bridget ^{[7
]}

Coppell, Jason ^{[15
]}

Laurie, John ^{[16
]}

Garg, Mamta ^{[17
]}

Ewing, Joanne ^{[18
]}

Knapper, Steve ^{[19
]}

Crowe, Josephine ^{[20
]}

Koutsavlis, Ioannis ^{[21
]}

Godfrey, Anna L. ^{[22
]}

Arami, Siamak ^{[23
]}

Drummond, Mark W. ^{[24
]}

Byrne, Jennifer ^{[22
]}

Clark, Fiona J. ^{[25
,26
]}

Mead-Harvey, Carolyn ^{[12
]}

Baxter, Joanna E. ^{[27
]}

McMullin, Mary Frances ^{[28
]}

Mead, Adam J. ^{[8
,9
,29
]}

机构：

[1] Guys & St Thomas NHS Fdn Trust, Dept Haematol, London, England

[2] Univ Cambridge, Wellcome MRC Cambridge Stem Cell Inst, Cambridge, England

[3] Wellcome Sanger Inst Hinxton, Hinxton, Cambs, England

[4] Cambridge Univ Hosp NHS Fdn Trust, Cambridge, England

[5] Univ Birmingham, Canc Res UK Clin Trials Unit, Birmingham, W Midlands, England

[6] Inst Canc Res, Clin Trials & Stat Unit, London, England

[7] Guys & St Thomas NHS Fdn Trust, London, England

[8] Univ Oxford, Med Res Council Weatherall Inst Mol Med, Oxford, England

[9] Univ Oxford, NIHR Biomed Res Ctr, Oxford, England

[10] Univ Birmingham, Clin Trials Unit, Canc Res UK, Birmingham, W Midlands, England

[11] Mayo Clin, Dept Internal Med, Scottsdale, AZ USA

[12] Mayo Clin, Dept Quantitat Hlth Sci, Scottsdale, AZ USA

[13] UT Hlth San Antonio, Mays Canc Ctr, San Antonio, TX USA

[14] Guys & St ThomasNHS Fdn Trust, Dept Histopathol, London, England

[15] Royal Devon & Exeter Hosp, Exeter, Devon, England

[16] Worthing Dist Hosp, Worthing, England

[17] Univ Hosp Leicester, Leicester, Leics, England

[18] Univ Hosp Birmingham NHS Fdn Trust, Birmingham, W Midlands, England

[19] Cardiff Univ, Sch Med, Cardiff, Wales

[20] Royal United Hosp, Bath, Avon, England

[21] Western Gen Hosp, Lothian Hlth Board, Edinburgh, Midlothian, Scotland

[22] Cambridge Univ Hosp NHS Fdn Trust, Dept Clin Haematol, Cambridge, England

[23] London North West Univ Healthcare NHS Trust, Harrow, Middx, England

[24] Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland

[25] Univ Hosp Birmingham NHS Fdn Trust, Queen Elizabeth Hosp, Birmingham, W Midlands, England

[26] Univ Hosp Birmingham NHS Fdn Trust, Queen Elizabeth Hosp, Cambridge, England

[27] Cambridge Blood & Stem Cell Biobank NHS BT Cambri, Haematol, Cambridge, England

[28] Queens Univ, Ctr Med Educ, Belfast, Antrim, North Ireland

[29] Oxford Univ Hosp NHS Fdn Trust, Churchill Hosp, Canc & Haematol Ctr, Oxford, England

来源：

BLOOD | 2022年 / 140卷

关键词：

D O I：

10.1182/blood-2022-157273

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1781 / 1783

页数：3

共 50 条

[31] Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial
Harrison, Claire N.
Vannucchi, Alessandro M.
Platzbecker, Uwe
Cervantes, Francisco
Gupta, Vikas
Lavie, David
Passamonti, Francesco
Winton, Elliott F.
Dong, Hua
Kawashima, Jun
Maltzman, Julia D.
Kiladjian, Jean-Jacques
Verstovsek, Srdan
LANCET HAEMATOLOGY, 2018, 5 (02): : E73 - E81
[32] Effect and Safety of Meropenem-Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial
Wunderink, Richard G.
Giamarellos-Bourboulis, Evangelos J.
Rahav, Galia
Mathers, Amy J.
Bassetti, Matteo
Vazquez, Jose
Cornely, Oliver A.
Solomkin, Joseph
Bhowmick, Tanaya
Bishara, Jihad
Daikos, George L.
Felton, Tim
Lopez Furst, Maria Jose
Kwak, Eun Jeong
Menichetti, Francesco
Oren, Ilana
Alexander, Elizabeth L.
Griffith, David
Lomovskaya, Olga
Loutit, Jeffery
Zhang, Shu
Dudley, Michael N.
Kaye, Keith S.
INFECTIOUS DISEASES AND THERAPY, 2018, 7 (04) : 439 - 455
[33] Cost-Effectiveness of Ruxolitinib Versus Best-Available Therapy for Medical Treatment of Myelofibrosis: Canadian Societal Perspective
El Ouagari, Khalid
Knight, Christopher John
Mendelson, Estella T.
BLOOD, 2012, 120 (21)
[34] EVALUATING THE COST-EFFECTIVENESS OF RUXOLITINIB FOR THE TREATMENT OF POLYCYTHAEMIA VERA PATIENTS THAT ARE RESISTANT/INTOLERANT TO HYDROXYCARBAMIDE/HYDROXYUREA IN ENGLAND AND WALES Rafia R,1 Dunham
Rafia, R.
Dunham, L.
Liu, A.
Brodie, J.
Hargreaves, V
Skinner, H.
Nawaz, A.
Baeza-Plaza, A.
Andrews, D.
Negi, H.
Jameson, K.
VALUE IN HEALTH, 2024, 27 (12) : S115 - S115
[35] Phase III randomized, open-label, active-controlled study of momelotinib versus best available therapy in ruxolitinib-treated patients with myelofibrosis.
Gupta, Vikas
Baer, Maria R.
Oh, Stephen T.
Miller, Carole Brennan
Jun, Susie
Lee, Peter
Dong, Hua
Reiter, Andreas
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[36] Markers of iron deficiency in patients with polycythemia vera receiving ruxolitinib or best available therapy
Verstovsek, Srdan
Harrison, Claire N.
Kiladjian, Jean-Jacques
Miller, Carole
Naim, Ahmad B.
Paranagama, Dilan C.
Habr, Dany
Vannucchi, Alessandro M.
LEUKEMIA RESEARCH, 2017, 56 : 52 - 59
[37] Clinical Benefit of Ruxolitinib Treatment after Crossover from Best Available Therapy in Patients with Polycythemia Vera: Analysis of the RESPONSE Trial
Kiladjian, Jean-Jacques
Vannucchi, Alessandro M.
Griesshammer, Martin
Masszi, Tamas
Durrant, Simon
Passamonti, Francesco
Harrison, Claire N.
Pane, Fabrizio
Zachee, Pierre
Mesa, Ruben
Jones, Mark M.
He, Shui
Li, Jingjin
Habr, Dany
Verstovsek, Srdan
BLOOD, 2014, 124 (21)
[38] Randomized Phase 3 Trial Evaluating the Efficacy and Safety of Ruxolitinib vs Best Available Therapy in Patients with Steroid-Refractory Acute Graft vs Host Disease (AGVHD)
Zeiser, Robert
von Bubnoff, Nikolas
Butler, Jason
Mohty, Mohamad
Niederwieser, Dietger
Or, Reuven
Szer, Jeff
Wagner, Eva Maria
Zuckerman, Tsila
Mahuzier, Bruyere
Xu, Judith
Gandhi, Kunal K.
Socie, Gerard
BONE MARROW TRANSPLANTATION, 2020, 55 (SUPPL 1) : 17 - 19
[39] Rilonacept for Colchicine-Resistant or -Intolerant Familial Mediterranean Fever A Randomized Trial
Hashkes, Philip J.
Spalding, Steven J.
Giannini, Edward H.
Huang, Bin
Johnson, Anne
Park, Grace
Barron, Karyl S.
Weisman, Michael H.
Pashinian, Noune
Reiff, Andreas O.
Samuels, Jonathan
Wright, Dowain A.
Kastner, Daniel L.
Lovell, Daniel J.
ANNALS OF INTERNAL MEDICINE, 2012, 157 (08) : 533 - +
[40] Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628)
von Bubnoff, Nikolas
Ihorst, Gabriele
Grishina, Olga
Roethling, Nadine
Bertz, Hartmut
Duyster, Justus
Finke, Juergen
Zeiser, Robert
BMC CANCER, 2018, 18

← 1 2 3 4 5 →